IL-17 receptor antibody formulation
US10808033B2 · kind B2 · utility
0Cited by
32References
6Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 2, 2018 |
| Grant date | Oct 20, 2020 |
| Priority date | — |
| Expiry date | Aug 21, 2038 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/76
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure relates to AM-14 pharmaceutical formulations and therapeutic dosing regimens for the treatment of disease.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.